139
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Linking the p53 tumor suppressor pathway to somatic cell reprogramming

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Reprogramming somatic cells to induced pluripotent stem (iPS) cells has been accomplished by expressing pluripotency factors and oncogenes 18, but the low frequency and tendency to induce malignant transformation 9 compromise the clinical utility of this powerful approach. We address both issues by investigating the mechanisms limiting reprogramming efficiency in somatic cells. We show that reprogramming factors can activate the p53 pathway. Reducing signaling to p53 by expressing a mutated version of one of its negative regulators, by deleting or silencing p53 or its target gene, p21, or by antagonizing apoptosis enhanced three factor (Oct4/Sox2/Klf4)-mediated reprogramming of mouse fibroblasts. Notably, decreasing p53 protein levels enabled fibroblasts to give rise to iPS cells capable of generating germline transmitting chimeric mice using only Oct4 and Sox2. Furthermore, silencing of p53 significantly increased the reprogramming efficiency of human somatic cells. These results provide insights into reprogramming mechanisms and suggest new routes to more efficient reprogramming while minimizing the use of oncogenes.

          Related collections

          Most cited references26

          • Record: found
          • Abstract: found
          • Article: not found

          Reprogramming of human somatic cells to pluripotency with defined factors.

          Pluripotency pertains to the cells of early embryos that can generate all of the tissues in the organism. Embryonic stem cells are embryo-derived cell lines that retain pluripotency and represent invaluable tools for research into the mechanisms of tissue formation. Recently, murine fibroblasts have been reprogrammed directly to pluripotency by ectopic expression of four transcription factors (Oct4, Sox2, Klf4 and Myc) to yield induced pluripotent stem (iPS) cells. Using these same factors, we have derived iPS cells from fetal, neonatal and adult human primary cells, including dermal fibroblasts isolated from a skin biopsy of a healthy research subject. Human iPS cells resemble embryonic stem cells in morphology and gene expression and in the capacity to form teratomas in immune-deficient mice. These data demonstrate that defined factors can reprogramme human cells to pluripotency, and establish a method whereby patient-specific cells might be established in culture.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Tumor suppressor p53 is a direct transcriptional activator of the human bax gene.

            The bax gene promoter region contains four motifs with homology to consensus p53-binding sites. In cotransfection assays using p53-deficient tumor cell lines, wild-type but not mutant p53 expression plasmids transactivated a reporter gene plasmid that utilized the bax gene promoter to drive transcription of chloramphenicol acetyltransferase. In addition, wild-type p53 transactivated reporter gene constructs containing a heterologous minimal promoter and a 39-bp region from the bax gene promoter in which the p53-binding site consensus sequences reside. Introduction of mutations into the consensus p53-binding site sequences abolished p53 responsiveness of reporter gene plasmids. Wild-type but not mutant p53 protein bound to oligonucleotides corresponding to this region of the bax promoter, based on gel retardation assays. Taken together, the results suggest that bax is a p53 primary-response gene, presumably involved in a p53-regulated pathway for induction of apoptosis.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2.

              Ectopic expression of defined sets of genetic factors can reprogram somatic cells to induced pluripotent stem (iPS) cells that closely resemble embryonic stem (ES) cells. The low efficiency with which iPS cells are derived hinders studies on the molecular mechanism of reprogramming, and integration of viral transgenes, in particular the oncogenes c-Myc and Klf4, may handicap this method for human therapeutic applications. Here we report that valproic acid (VPA), a histone deacetylase inhibitor, enables reprogramming of primary human fibroblasts with only two factors, Oct4 and Sox2, without the need for the oncogenes c-Myc or Klf4. The two factor-induced human iPS cells resemble human ES cells in pluripotency, global gene expression profiles and epigenetic states. These results support the possibility of reprogramming through purely chemical means, which would make therapeutic use of reprogrammed cells safer and more practical.
                Bookmark

                Author and article information

                Journal
                0410462
                6011
                Nature
                Nature
                0028-0836
                1476-4687
                19 August 2009
                9 August 2009
                27 August 2009
                27 February 2010
                : 460
                : 7259
                : 1140-1144
                Affiliations
                [1 ] Gene Expression Laboratory, Salk Institute for Biological Studies, 10010 North Torrey Pines Rd., La Jolla, California 92037, USA
                [2 ] Career-Path Promotion Unit for Young Life Scientists, Kyoto University, Kyoto, 606-8501, Japan
                [3 ] Drug Discovery Research, Astellas Pharma Inc., Tsukuba, Ibaraki 305-8585, Japan
                [4 ] Center of Regenerative Medicine in Barcelona, Dr. Aiguader 88, 08003 Barcelona, Spain
                [5 ] Institució Catalana de Recerca i Estudis Avançats (ICREA) and Networking Center of Biomedical Research in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN)
                Author notes
                Reprints and permissions information is available at www.nature.com/reprints. Correspondence and requests for materials should be addressed to J.C.I.B. ( belmonte@ 123456salk.edu ) and G.W. ( wahl@ 123456salk.edu )
                [*]

                These authors contributed equally to this work

                Article
                nihpa134470
                10.1038/nature08311
                2735889
                19668186
                3552dcd3-434f-4fdd-98a5-82bd8667e100

                Users may view, print, copy, download and text and data- mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms

                History
                Funding
                Funded by: National Heart, Lung, and Blood Institute : NHLBI
                Funded by: National Cancer Institute : NCI
                Award ID: R33 HL088293-03 ||HL
                Funded by: National Heart, Lung, and Blood Institute : NHLBI
                Funded by: National Cancer Institute : NCI
                Award ID: R01 CA100845-05 ||CA
                Funded by: National Heart, Lung, and Blood Institute : NHLBI
                Funded by: National Cancer Institute : NCI
                Award ID: R01 CA061449-30 ||CA
                Categories
                Article

                Uncategorized
                Uncategorized

                Comments

                Comment on this article